OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Gastroenterology & Hepatology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Regulating protease homeostasis in irritable bowel syndrome	641
Hybrid EASL Congress 2023	484
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity	447
Zolbetuximab treatment in metastatic gastric cancer	425
2023 FDA approvals in gastroenterology and hepatology	404
Western lifestyle, metaflammation and the cell of origin of colon cancer	349
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	340
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	326
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	313
Digestive Disease Week 2022	305
Mapping neuroimmune interactions in the gut	301
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	282
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	275
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	266
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	257
Nomenclature of HBV core protein-targeting antivirals	252
Artificial intelligence and automation in endoscopy and surgery	239
Leveraging diet to engineer the gut microbiome	216
Hepatic IRF3 in glucose intolerance	201
Oral microbiome therapy efficacious for recurrent C. difficile infection	201
Wound healing in the colon	191
A crucial Fusobacterium nucleatum clade in colorectal cancer	185
GWAS reveals variants for alcohol-related hepatocellular carcinoma	176
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	169
Metastatic pancreatic cancer and the liver	168

Decoding therapy resistance in liver tumours: a giant leap	161
A deep dive into the submerged ‘coeliac iceberg’	159
New understanding of hepatobiliary MRI	157
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	156
Inflammatory bowel disease in pregnancy and breastfeeding	152
Bacteriophages and their potential for treatment of gastrointestinal diseases	151
The global burden of coeliac disease: opportunities and challenges	151
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	145
Advancing on pancreatic cancer	144
Dietary carbohydrates and fats in nonalcoholic fatty liver disease	143
HDCA ameliorates NAFLD in mice	140
Integrated systems approach to identify environmental factors in intestinal inflammation	139
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	139
Metabolic diseases in the East Asian populations	133
Therapeutic base editing in the adult liver	128
Lanifibranor and NASH resolution	127
Probiotics for preterms: sharing complex decision-making	121
Implications of the evolving knowledge of the genetic architecture of MASLD	118
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	111
Medical therapy of paediatric inflammatory bowel disease	110
Preventing the progression of cirrhosis to decompensation and death	108
Estimating dietary intake from human stool DNA	108
Characterizing the genomic landscape of colorectal cancer	106
SSRIs and depression: role of gut–brain communication	101
Human intestinal B cells in inflammatory diseases	101
Transglutaminase 2 inhibitor for coeliac disease	100
The path to successful hepatitis C elimination in Spain	100
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	100
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	97
Current and future colorectal cancer screening strategies	97
ECCO’24	96
Transforming the landscape of liver cancer detection and care	95
Author Correction: Hepatic immune regulation and sex disparities	92
A single-cell atlas of fibroblasts: one size does not fit all	91
Yeast probiotics for the treatment of IBD	91
NAFLD prevalence in older patients with T2DM	89
Phase III results for first-line treatment for metastatic colorectal cancer	88
Microbiota and colorectal cancer — controlling for confounders challenges associations	85
Gut microbiome and autism spectrum disorder	85
Enteric nervous system transfers stress to the gut	83
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	82
GLP1R agonists in NAFLD: a promising therapy on the horizon	82
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	80
Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	79
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	76
Hepatic glucose metabolism in the steatotic liver	76
Artificial intelligence in liver cancer — new tools for research and patient management	76
Foundations of gastrointestinal-based drug delivery and future developments	76
Immunoregulatory role of enteric glia	73
Hepatic inflammatory responses in liver fibrosis	73

SMART cancer risk prediction	72
Liver dialysis in ACLF	71
AI predicts pancreatic cancer risk	69
Elucidating the transmission landscape of the human microbiome	65
The gut microbiome in feast and famine	65
Nifty new tools for microbiome treatment design	64
Gut bacteria go on record	64
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel	62
A new era in obesity management	62
International collaborative research to improve gallbladder cancer prevention	60
Postbiotics — when simplification fails to clarify	59
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	57
MASLD as a non-communicable disease	57
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	53
Hepatitis E virus: from innate sensing to adaptive immune responses	50
Revisiting fibrosis in inflammatory bowel disease: the gut thickens	48
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests	47
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	47
Danger! P2Y14 receptor links cell death to liver fibrosis	45
Tirzepatide to treat obesity: phase III results	44
Publisher Correction: Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	43
Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma	41
Cathepsin S in liver fibrogenesis	39
Origin of CAFs in colorectal cancer	39
A novel pathomics signature for gastric cancer	39
Antibiotic-perturbed microbiota and the role of probiotics	38
Cellular and molecular basis of proximal small intestine disorders	38
The steatotic liver disease burden paradox: unravelling the key role of alcohol	36
Bridging the gap: increasing MENA representation in MASLD clinical trials	35
Commensal fungi in intestinal health and disease	34
Natural history of NAFLD: knowns and unknowns	34
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	34
Classifying compounds as prebiotics — scientific perspectives and recommendations	31
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	30
Author Correction: Improving IBD outcomes in the era of many treatment options	30
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	30
Therapeutic landscape and future direction of metastatic colorectal cancer	30
Long-term normothermic liver perfusion	30
Justice, equity, diversity and inclusion in gastroenterology and hepatology	29
Author Correction: Current and future colorectal cancer screening strategies	28
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	28
Diet-driven microbiome restoration associated with cardiometabolic benefits	26
Alcohol-free and low-strength drinks: friend or foe?	25
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	25
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	24
Global epidemiology of cirrhosis — aetiology, trends and predictions	24
A Roadmap for the Human Gut Cell Atlas	24
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	24
Hippo signalling in the liver: role in development, regeneration and disease	24
Resmetirom safe for nonalcoholic fatty liver disease	23
Intermittent fasting for NASH and HCC in mice	22
Digestive Disease Week 2023	22
New target and timing in PDAC immunotherapy?	22
Location, location, location — spatial insight into hepatic macrophage populations	22
Deciphering potential implications of dietary microplastics for human health	21
Digestive Disease Week 2025	21
A resource for the food microbiome and its links with the human microbiome	21
ECCO’25	21
Elafibranor in primary biliary cholangitis	21
Gastrointestinal health and the environment: a bidirectional relationship	20
Food inequity and insecurity and MASLD: burden, challenges, and interventions	20
Follow-up of SER-109 for recurrent C. difficile	20
Envisioning how to advance the MASH field	20
Human liver tissue in a mouse host	20
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	20
HCV direct-acting antiviral therapy adherence in people who inject drugs	19
Nanoparticles in NAFLD therapeutics	19
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	19
Amitriptyline as second-line treatment for IBS in primary care settings	18
Envisioning adalimumab for paediatric patients with ulcerative colitis	18
Lactylation and HCC progression	17
COVID-19 and liver disease: where are we now?	17
Gastrointestinal post-acute COVID-19 syndrome	17
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	17
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	17
IL-17A-producing CD8+ T cells in pancreatic cancer	17
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	16
Early detection of pancreatic cancer using DNA-based molecular approaches	16
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	16